Shanghai Henlius Biotech (HKG:2696) said the United States Food and Drug Administration approved its investigational new drug application of innovative small molecular HLX99, a Monday bourse filing said.
The drug is a small molecule coupled chemical drug and is purposed for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that causes loss of muscle innervation.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。